Apr 23, 2020
Henlius receives EU GMP Certificate for HLX02 (Trastuzumab for Injection)
Apr 23, 2020
New Early Breast Cancer Drug Available Now In Singapore
Apr 21, 2020
IMBRUVICA® (ibrutinib) Receives 11th FDA Approval
Apr 21, 2020
U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
Apr 09, 2020
Roche's Ocrevus Continues to Impress in the EU with Strong Uptake in New Start and Switch Multiple Sclerosis Patient Segments, but Novartis' Mayzent and Ofatumumab May Threaten the Brand's Long-Term Dominance
Apr 07, 2020
Curis to Present at 19th Annual Needham Virtual Healthcare Conference
Apr 03, 2020
Case Study: Treating COVID-19 in a Patient with Multiple Myeloma
Apr 01, 2020
The Leukemia & Lymphoma Society And Partners Commit $4.5 Million For Blood Cancer Patients Impacted By COVID-19
Apr 01, 2020
Trovagene Announces Acceptance of Phase 1b/2 KRAS-Mutated Metastatic Colorectal Cancer (mCRC) Trial Abstract for Presentation at the 2020 ASCO Annual Meeting
Mar 23, 2020
2020 Pipeline Insight on Insulin Resistance
Mar 19, 2020
Hoth Therapeutics Announces Positive Preclinical Data of WEG232 Treatment, Developed for Cancer Patients Suffering from Erlotinib-Induced Facial Dermatitis and Hair Loss
Mar 18, 2020
GSK, AstraZeneca, Genentech, and Novartis Identified as the Top Companies Driving Therapeutic Innovation in Asthma
Mar 16, 2020
InxMed Announces Dosing of First Patient in a Phase Ib Trial of IN10018 as Monotherapy and Combination Therapy in Patients with Uveal Melanoma and NRAS mutant Metastatic Melanoma in the United States
Mar 16, 2020
Leap Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
Mar 12, 2020
Curis to Release Fourth Quarter and Year-End 2019 Financial Results and Hold Conference Call on March 19, 2020
Mar 12, 2020
AbbVie Receives European Commission Approval of VENCLYXTO® Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia
Mar 10, 2020
Genentech's Ocrevus Offers Stiff Competition to the New High-Efficacy Oral Therapies, Novartis' Mayzent and EMD Serono's Mavenclad, While Biogen's Vumerity Begins to Chip Away at the Company's Own Tecfidera
Mar 10, 2020
2020 Disease Analysis: Multiple Sclerosis - Sanofi to Co-Develop Digital Therapeutic for MS Patients
Mar 10, 2020
Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update
Mar 09, 2020
Insights on Triple-Negative Breast Cancer - Approval and Subsequent Uptake of New Targeted Therapies and Immunotherapies Driving Growth